Experienced in Embryonal Tumor with Multilayered Rosettes

Dr. Benjamin L. Maughan

Hematology Oncology | Hematology | Oncology
University Of Utah Adult Services
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
Accepting New Patients
Experienced in Embryonal Tumor with Multilayered Rosettes
University Of Utah Adult Services
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Benjamin Maughan is a Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Maughan is rated as an Experienced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Prostate Cancer, Hemangioblastoma, Renal Cell Carcinoma (RCC), Penectomy, and Tissue Biopsy. Dr. Maughan is currently accepting new patients.

His clinical research consists of co-authoring 120 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Hospital Affiliations
University Of Utah Hospital And Clinics
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
PacificSource
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

UNIVERSITY OF UTAH ADULT SERVICES
1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Enrollment Status: Completed
Publish Date: October 01, 2024
Intervention Type: Drug
Study Phase: Phase 1
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Phase 2 Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Tremelimumab
Study Phase: Phase 2
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Neoadjuvant Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Gemcitabine, Cisplatin
Study Phase: Phase 2
Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer
Enrollment Status: Completed
Publish Date: May 16, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating BRCAness Genotype (ROAR)
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating BRCAness Genotype (ROAR)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer
A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer
Enrollment Status: Terminated
Publish Date: May 22, 2023
Intervention Type: Drug
Study Drug: Muscadine Plus
Study Phase: Phase 3
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Enrollment Status: Completed
Publish Date: April 27, 2022
Intervention Type: Biological
Study Drugs: CV-301, Atezolizumab
Study Phase: Phase 2
Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
Enrollment Status: Withdrawn
Publish Date: September 22, 2021
Intervention Type: Combination product
Study Drug: MVA-BN-Brachyury
Study Phase: Phase 2
ACADEMIC: A Randomized Phase II Clinical Trial of ADT Combined With Abiraterone or Docetaxel in Metastatic Hormone Sensitive Prostate Cancer
ACADEMIC: A Randomized Phase II Clinical Trial of ADT Combined With Abiraterone or Docetaxel in Metastatic Hormone Sensitive Prostate Cancer
Enrollment Status: Terminated
Publish Date: June 25, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

120 Total Publications

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.
Journal: JAMA network open
Published: October 02, 2025
Similar Doctors
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Clarke A. Low
Hematology Oncology | Oncology | Hematology
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Clarke A. Low
Hematology Oncology | Oncology | Hematology

Ihc Health Services Inc

5171 S Cottonwood St, Suite 610, 
Murray, UT 
 (8.5 miles away)
801-507-3630
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Clarke Low is a Hematologist Oncology specialist and an Oncologist in Murray, Utah. Dr. Low is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Astrocytoma, Embryonal Tumor with Multilayered Rosettes, Glioblastoma, and Gliosarcoma. Dr. Low is currently accepting new patients.

Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Nathan T. Rich
Hematology Oncology | Oncology | Hematology
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Nathan T. Rich
Hematology Oncology | Oncology | Hematology

Utah Cancer Specialists PC

395 W Bulldog Blvd, Suite 103, 
Provo, UT 
 (37.3 miles away)
801-357-8200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nathan Rich is a Hematologist Oncology specialist and an Oncologist in Provo, Utah. Dr. Rich is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Thrombotic Thrombocytopenic Purpura, Small Cell Lung Cancer (SCLC), Chronic Lymphocytic Leukemia (CLL), and Paget Disease of the Breast. Dr. Rich is currently accepting new patients.

Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Gregory C. Chipman
Oncology | Hematology | Hematology Oncology
Advanced in Embryonal Tumor with Multilayered Rosettes
Dr. Gregory C. Chipman
Oncology | Hematology | Hematology Oncology

Utah Cancer Specialists PC

5131 S Cottonwood St, 2 Utah Cancer Specialists, 
Murray, UT 
 (8.2 miles away)
801-263-3416
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Gregory Chipman is an Oncologist and a Hematologist in Murray, Utah. Dr. Chipman is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Non-Hodgkin Lymphoma, Familial Colorectal Cancer, Paget Disease of the Breast, and Familial Pancreatic Cancer. Dr. Chipman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Maughan's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile